永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

休市中 06-18 16:08:07

0.520

-0.060

-10.34%

最高0.570	最低0.520	成交量67.00万
今开0.520	昨收0.580	日振幅8.62%
总市值3.21亿	流通市值3.21亿	总股本6.18亿
成交额35.74万	换手率0.11%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.52,"timestamp":1781770087294,"preClose":0.58,"halted":0,"volume":670000,"delay":0,"changeRate":-0.10344827586206887,"floatShares":618000000,"shares":618000000,"eps":-0.4849938875305624,"marketStatus":"休市中","change":-0.06,"latestTime":"06-18 16:08:07","open":0.52,"high":0.57,"low":0.52,"amount":357390,"amplitude":0.086207,"askPrice":0.52,"askSize":42000,"bidPrice":0.51,"bidSize":103000,"shortable":0,"etf":0,"ttmEps":-0.4780654034229829,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782091800000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.58,"openAndCloseTimeList":[[1781746200000,1781755200000],[1781758800000,1781769600000]],"volumeRatio":1.951071778886689,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978/tweets","defaultTab":"tweets","newsList":[{"id":"2644942700","title":"创新药概念震荡反弹，关注创新药ETF易方达（516080）配置价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2644942700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644942700?lang=zh_cn&edition=full","pubTime":"2026-06-18 19:06","pubTimestamp":1781780776,"startTime":"0","endTime":"0","summary":"6月18日，创新药概念震荡反弹，截至收盘，恒生港股通创新药指数上涨1.8%，中证港股通医药卫生综合指数上涨1.8%，中证创新药产业指数上涨2.6%，中证生物科技主题指数上涨1.7%，沪深300医药卫生指数上涨1.0%。中泰证券指出，当前医药板块估值处于历史低位，近期药企密集回购彰显管理层信心，板块底部配置价值进一步强化，尤其看好创新药领域的底部投资机会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026061800035998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","516080","159992","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644170386","title":"6月18日众生药业（002317）涨停分析：减肥药、MASH创新药、流感药驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2644170386","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644170386?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:41","pubTimestamp":1781768485,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业6月18日涨停收盘，收盘价22.9元。6月18日众生药业涨停的可能因素有：RAY1225减肥药II期临床数据亮眼，亮相ADA大会并完成III期入组；ZSP1601治疗MASH的IIb期顶线数据积极，疗效显著优于安慰剂；昂拉地韦颗粒获CDE优先审评，儿童流感适应症进展顺利；公司2025年扭亏为盈、2026Q1净利润同比增20.83%，创新药管线加速兑现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800022267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","002317","06978","BK0239","BK0188","159992","BK1574","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644523771","title":"一品红(300723.SZ)：子公司创新药APH03867片获得临床试验注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2644523771","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644523771?lang=zh_cn&edition=full","pubTime":"2026-06-18 12:01","pubTimestamp":1781755286,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03867片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。据悉，APH03867片是公司自主研发的一种新型口服、非肽类小分子URAT1(全称：Urate Transporter 1，中文译为：尿酸转运蛋白1)抑制剂，通过抑制肾脏中URAT1的活性，阻断尿酸在肾小管的重吸收，增加尿酸排泄，达到有效降低血尿酸的效果，可用于改善高尿酸血症和痛风症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0239","300723","159992","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644830771","title":"恩华药业：公司一类创新药NH600001的审批进展一切正常顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2644830771","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644830771?lang=zh_cn&edition=full","pubTime":"2026-06-18 11:54","pubTimestamp":1781754843,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业(002262)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，网传公司创新药发补要拖到明年了，是否属实？谢谢！恩华药业回复：公司一类创新药NH600001的审批进展一切正常顺利！有关公司新药开发的重要信息一切以公司公告为准。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800018446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0070","BK0188","BK1574","LU1064130708.USD","LU1064131003.USD","06978","LU2148510915.USD","BK0239","002262","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644314776","title":"创新药概念普涨 再鼎医药(09688)升逾6% 机构指该板块仍将为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2644314776","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644314776?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:21","pubTimestamp":1781749308,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念普涨，截至发稿，再鼎医药 涨6.34%，康方生物涨5.96%，药明康德涨3.59%，康诺亚-B涨3.49%，亚盛医药涨3.45%，药明生物涨3.08%，金斯瑞生物科技涨2.93%，百济神州涨2.60%。华鑫证券研究称，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"84bb90b0e003ec2bc59dc9b9cb81d467","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984066","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","02359","LU2242644610.SGD","LU0588546209.SGD","LU1969619763.USD","LU2476274308.USD","LU0307460666.USD","SG9999002463.SGD","LU0516423174.USD","LU1720050803.USD","09926","BK4526","LU0326950275.SGD","02269","BK1521","HK0000306701.USD","LU2488822045.USD","LU1794554557.SGD","06855","LU0561508036.HKD","BK1589","09688","LU1961090484.USD","06160","BK1583","LU0516422366.SGD","LU1719994722.HKD","ZLAB","LU2328871848.SGD","BK1161","LU0348784397.USD","02162","LU0516422952.EUR","01548","LU2045819591.USD","BK4531","LU0979878070.USD","LU0456846285.SGD","BK1587","HK0000320223.HKD","LU0516423091.SGD","LU0348827113.USD","LU1303224171.USD","06978","LU0417516571.SGD","BK1141","BK1588","LU0140636845.USD","IE00BPRC5H50.USD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177778204","title":"港股创新药概念股盘中走高！再鼎医药涨超6%，康方生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177778204","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177778204?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:20","pubTimestamp":1781749207,"startTime":"0","endTime":"0","summary":"6月18日，港股创新药概念股盘中走高，$再鼎医药(ZLAB)$涨超6%，$康方生物(09926)$涨超5%，$亚盛医药(06855)$、$百济神州(06160)$、$药明生物(02269)$、$药明康德(02359)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"84bb90b0e003ec2bc59dc9b9cb81d467","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","LU0348784397.USD","BK4585","159992","BK4531","LU2488822045.USD","BK1588","LU0348735423.USD","VXUS","LU2476274308.USD","BK4526","09688","LU0348827113.USD","LU0348825331.USD","LU1720050803.USD","LU0417516738.SGD","IE00BPRC5H50.USD","BK4139","LU2399975544.HKD","LU0417516902.SGD","ZLAB","IE00B5MMRT66.SGD","LU0348783233.USD","BK4548","LU1794554557.SGD","LU0561508036.HKD","06978","BK4588","IE00B543WZ88.USD","LU0417516571.SGD","LU0634319403.HKD","LU0348767384.USD","BK1161","BK1574","LU0540923850.HKD","LU2476274720.SGD","LU1961090484.USD","LU0348766576.USD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644877638","title":"博瑞医药二闯港股IPO：创新药烧钱不止，原料药基本盘失守","url":"https://stock-news.laohu8.com/highlight/detail?id=2644877638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644877638?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:18","pubTimestamp":1781749116,"startTime":"0","endTime":"0","summary":"据招股书披露，博瑞医药现阶段研发重心集中两大方向：全球创新专业的代谢疾病疗法，以及具有竞争力的吸入式药械组合产品系列。博瑞医药在招股书高调宣称其“具备全球同类最佳潜力”。博瑞医药在2025年年报中提到，受流感趋势变化及竞争格局变化影响，奥司他韦原料药及制剂需求及价格产生下滑，使得抗病毒类产品收入、毛利额均大幅减少。2025年，博瑞医药在全球磷酸奥司他韦原料药及中间体市场的市场份额仅为2.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026061800012453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","BK0239","06978","688166","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644714731","title":"热景生物(688068.SH)子公司创新药SGT003注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2644714731","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644714731?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:05","pubTimestamp":1781687144,"startTime":"0","endTime":"0","summary":"智通财经APP讯，热景生物 发布公告，近日，公司子公司北京舜景生物医药技术有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，舜景医药研制的创新药SGT003注射液临床试验申请已获得国家药品监督管理局批准。公告显示，SGT003注射液是一款基于舜景医药自主构建的NexTreg技术平台开发的全球首款进入临床研究的新型双特异性抗体候选药物，其核心创新在于精准清除肿瘤微环境调节性T细胞，激活抗肿瘤免疫。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688068","BK1574","BK0239","BK1161","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644716552","title":"众生药业：昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2644716552","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644716552?lang=zh_cn&edition=full","pubTime":"2026-06-17 15:21","pubTimestamp":1781680867,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问：已经26年6月中旬了，昂拉地韦片25年销量数据还没有公布，需要讳莫如深吗？还是害怕像新冠特效药那样？众生药业回复：您好！昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药，适用于成人单纯性甲型流感患者的治疗，销售与流感季节性相关。公司正持续推进学术推广与渠道建设，后续将结合流感周期与医保落地效应，稳步推动昂拉地韦片的商业化工作。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700020366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002317","BK1161","06978","BK0239","BK0188","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644182357","title":"港股异动 | 励晶太平洋(00575)一度飙升110% 旗下创新药Senstend™获国家药监局上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2644182357","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644182357?lang=zh_cn&edition=full","pubTime":"2026-06-17 13:55","pubTimestamp":1781675740,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，励晶太平洋今日一度飙涨超110% ，截至发稿，涨80.7%，报1.03港元，成交额264.96万港元。消息面上，励晶太平洋宣布，旗下创新疗法 Senstend 的新药申请已正式获得国家药品监督管理局的上市批准，并附带为期四年数据保护期。此外，随着江苏万邦医药预计将于2026年下半年启动首次商业销售，届时将再度触发向励晶太平洋支付200万美元。因此，集团预计将于2026年内稳健收取合共700万美元的现金付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","00575","VXUS","BK1161","BK4588","BK4585","06978","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644992317","title":"恩华药业：NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2644992317","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644992317?lang=zh_cn&edition=full","pubTime":"2026-06-17 08:52","pubTimestamp":1781657529,"startTime":"0","endTime":"0","summary":"证券之星消息，恩华药业06月17日在投资者关系平台上答复投资者关心的问题。恩华药业回复：NH600001是公司首款自主立项、自主临床、自主申报的化药1类创新药，标志着公司从仿制药向自主创新药转型。该药品克服了依托咪酯抑制肾上腺皮质功能的副作用，同时保留了其起效快、苏醒平稳迅速、对呼吸循环影响小的优势。预计该产品获批上市后有望快速扩大销售规模，是公司未来增长的重要引擎之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700007404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0239","BK1574","LU2148510915.USD","06978","LU1064130708.USD","LU1064131003.USD","BK1161","BK0070","159992","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643763638","title":"绿叶制药(02186)创新药LY03015(VMAT2抑制剂╱Sigma-1R激动剂)治疗迟发性运动障碍的中国Ⅱ期临床研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2643763638","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643763638?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:20","pubTimestamp":1781619613,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药 发布公告，集团自主研发的1类创新药LY03015用于治疗迟发性运动障碍的中国Ⅱ期临床试验已完成，取得积极结果，达到主要终点。LY03015为全球首个进入临床的囊泡单胺转运体2和Sigma-1R双靶点创新药，目标适应症为TD和亨廷顿病相关的舞蹈症。集团通过自主建立的AI药物设计平台，设计了全新结构的小分子药物LY03015，不仅解决了上述安全性风险，而且高活性靶向VMAT2和Sigma-1R，发挥“症状控制”和“病理改善”的双重作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1161","02186","BK1583","BK1606","159992","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643784676","title":"在成长与安全之间寻找平衡点 公私募探讨下半年科技投资大方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2643784676","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643784676?lang=zh_cn&edition=full","pubTime":"2026-06-16 07:11","pubTimestamp":1781565106,"startTime":"0","endTime":"0","summary":"【在成长与安全之间寻找平衡点 公私募探讨下半年科技投资大方向】一边是激荡的人工智能产业浪潮，以及地缘局势不确定性的缓解，令市场参与者心潮澎湃、不敢缺席；另一边却是相关个股在经历前期大幅上涨后，估值攀升至历史高位。站在当前时点，在深度认可科技主线的同时，公私募下半年如何更好地应对市场波动，并发掘新的投资机会？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11791,202606163771945955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["AI","BK4588","CHAT","BK4587","BK1161","AGIX","BK4528","BK4551","BK4023","BK4543","BK1574","ARTY","06978","AIPO","AIYY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643753762","title":"海思科：公司负责礼来选定的最多五个靶点创新药项目的发现及早期研发工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2643753762","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643753762?lang=zh_cn&edition=full","pubTime":"2026-06-15 15:51","pubTimestamp":1781509872,"startTime":"0","endTime":"0","summary":"证券之星消息，海思科(002653)06月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，海思科买礼来的品种，如何进行定价？是否需要履行评估手续？海思科回复：您好，根据公司与礼来的合作协议，公司将负责礼来选定的最多五个靶点创新药项目的发现及早期研发工作，并非公司从礼来购买品种，不涉及定价和评估，感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500015564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0033","BK0077","BK0188","159992","BK1161","06978","002653","BK0239","BK0028","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643227978","title":"多家药企宣布回购增持计划，能否挽救创新药板块低迷情绪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2643227978","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643227978?lang=zh_cn&edition=full","pubTime":"2026-06-15 14:03","pubTimestamp":1781503380,"startTime":"0","endTime":"0","summary":"在国内生物医药板块持续走低的背景下，多家国内创新药企宣布了回购或增持计划，向市场传递信心。　　6月15日早盘，港股龙头药企中国生物制药公告称，公司董事会决议通过一项股份购买计划，将视市场情况于未来12个月以不超过20亿港元总价在公开市场上回购本公司股份，及指示负责管理股份奖励计划的受托人购买股份。据不完全统计，这是今年以来创新药企业最大金额的回购计划。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-15/doc-inicnisv8303280.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-15/doc-inicnisv8303280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643722457","title":"上海创新药开启胃癌“免化疗” ，全球首款胃癌围术期免疫单药方案落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2643722457","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643722457?lang=zh_cn&edition=full","pubTime":"2026-06-15 11:45","pubTimestamp":1781495148,"startTime":"0","endTime":"0","summary":"2026年美国临床肿瘤学会年会（ASCO）的口头报告现场，由北京大学肿瘤医院沈琳教授公布一项胃癌重磅III期临床研究（ASTRUM-006）。这份报告正是斯鲁利单抗胃癌围术期适应症的核心研究。全球首个实现胃癌围术期术后“去化疗”的抗PD-1单抗近日正式在中国获批——来自上海复宏汉霖自主研发的创新药，成为目前全球唯一获批胃癌围术期适应症的PD-1抑制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606153771328852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643124127","title":"新股消息 | “肾病创新药第一股”敲门港股：礼邦医药过聆讯 核心管线进入兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2643124127","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643124127?lang=zh_cn&edition=full","pubTime":"2026-06-14 21:49","pubTimestamp":1781444964,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所6月14日披露，专注肾病的礼邦医药今日通过港交所主板上市聆讯，杰富瑞、美银证券及华泰证券联席保荐，有望成为港股“肾病创新药第一股”。核心产品AP301被列为一类新药，治疗高磷血症，已完成中国III期临床并将提交NDA，正在美国和中国开展全球III期MRCT。全球高磷血症临床阶段仅2个分子，礼邦独占两席。2025年全球高磷血症药物市场规模180亿美元，预计2035年达640亿美元；中国市场从18亿元增至107亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","VXUS","BK1161","BK4585","159992","159938","06978","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642257792","title":"港股异动 | 创新药概念多数走高 行业BD交易延续高景气 政策支持与商业化盈利兑现逻辑不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2642257792","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642257792?lang=zh_cn&edition=full","pubTime":"2026-06-12 14:50","pubTimestamp":1781247029,"startTime":"0","endTime":"0","summary":"消息面上，今年一季度，中国创新药对外授权交易总额突破600亿美元，显示出海已从“偶发大单”升级为可持续的产业能力；另一方面，ASCO 2026中国研究入选数量和学术层级也在继续提升。近期多个创新药数据读出，重要BD陆续公告，事件性催化不断；中国创新药全球竞争力持续加强，政策支持与商业化盈利兑现的产业逻辑不变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK4588","LU0359201612.USD","LU0359202008.SGD","LU0196878994.USD","LU2543165471.USD","06990","LU1969619763.USD","LU2328871848.SGD","BK1574","09969","BK1161","BK4585","BK1583","01276","LU0359201885.HKD","09995","BK1191","VXUS","159992","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642818052","title":"今年“双目录”申报已完成，同时申报医保目录和商保目录44份","url":"https://stock-news.laohu8.com/highlight/detail?id=2642818052","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642818052?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:40","pubTimestamp":1781178000,"startTime":"0","endTime":"0","summary":"6月11日，据国家医保局消息，2026年基本医保目录及商保创新药目录调整申报已于6月10日20：00结束。申报期间共收到818份药品申报材料，包括目录外药品570份，目录内药品248份，总体数量较2025年进一步增加。今年“双目录”启动申报将较往年提前1个月左右。5月31日，国家医保局正式发布《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-06-11/doc-iniaztwr0798327.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-06-11/doc-iniaztwr0798327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642891712","title":"创新药板块今日承压，关注港股通创新药ETF易方达（159316）中长期发展机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2642891712","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642891712?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:20","pubTimestamp":1781176857,"startTime":"0","endTime":"0","summary":"6月11日，医药板块走势分化，创新药方向有所承压，截至收盘，恒生港股通创新药指数下跌1.1%，中证港股通医药卫生综合指数下跌1.0%，中证创新药产业指数下跌0.5%，中证生物科技主题指数下跌0.7%，沪深300医药卫生指数上涨0.1%。有分析认为，尽管短期市场情绪波动使得创新药板块承压，但从产业生态来看，审批通道的成熟、支付体系的完善以及管线临床数据的持续兑现，构成了创新药赛道中长期发展的坚实基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026061100033085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","516080","159316","BK1161","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0714},{"period":"1month","weight":-0.3659},{"period":"3month","weight":-0.7953},{"period":"6month","weight":-0.8194},{"period":"1year","weight":-0.8272},{"period":"ytd","weight":-0.8225}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0726},{"period":"3month","weight":-0.0535},{"period":"6month","weight":-0.0687},{"period":"1year","weight":0.009},{"period":"ytd","weight":-0.0666}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073624},{"month":6,"riseRate":0.666667,"avgChangeRate":0.01172},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}